spending in private US biopharmaceutical fi rms before they go public and whether or not these fi rms tap into external sources of funding for investment before an initial public offering. We focus our study on three specifi c sources of funding (venture capital investors, biopharmaceutical fi rm investors and strategic alliance partners) for two different time periods (one year prior to fi rms going public and cumulative years prior to going public). We found an increase in R & D spending over the course of the study and a positive relationship between R & D spending in the year prior to its going public and venture capital involvement. We also found a positive relationship between the cumulative amount spent on R & D and venture capital involvement and ownership by other biopharmaceutical fi rms. We use the literature on tradable assets and signaling theory to interpret the implications of our fi ndings. For managers, the results suggest that if their goal is to send signals to future investors by way of spending greater amounts on R & D in the year prior to going public, then venture capital investors are more likely to be associated with this type of activity.
INTRODUCTION
Increasingly, medical innovation is having a profound effect on Americans ' lives. Perhaps, nowhere is this more apparent than in the Original Article R & D spending and sources of funding of private US biopharmaceutical fi rms seeking to go public biopharmaceutical industry (that is, biotechnology and pharmaceutical fi rms) where new disruptive technologies and drugs are creating a paradigm shift for both developers of drugs and providers of patient care. 1 With this shift has come new privatepublic relationships that are transforming communities as states, academia, corporations and fi nanciers have sought to create geographic clusters for this industry. 2 -4 These shifts have also fueled rising biopharmaceutical costs as Americans in 2006 spent fi ve times more on drugs and therapies than they did in 1990. 5 US biopharmaceutical fi rms also spent approximately fi ve times more on research and development (R & D) in 2003 compared with 1990 6 and more than US $ 65 billion on R & D in 2008 alone. 7 The majority of these R & D efforts, however, never make it to market 8 and for those few that do make it to market, most are not profi table. 9 Yet despite these increased efforts, we know very little about these phenomena. 10 Seeking to expand our knowledge, this article examines two critical functions of new biopharmaceutical fi rms: R & D spending and the fi nancing of this R & D spending. Our central premise is that given the cost requirements of new drug development, it is logical to suppose that those fi rms engaging in drug discovery and development with greater access to suppliers of resources (for example, venture capitalists, biopharmaceutical fi rm investors and strategic alliance partners) would also spend greater amounts on R & D before going public.
We choose new private biopharmaceutical fi rms to study because early in the life cycle of these fi rms the majority of funds available are dedicated to R & D activities. 11 We investigate these fi rms at the time that they are seeking to go public, as research suggests that this is the time when fi rms are most in need of funding and represents a milestone event for many fi rms in this industry. 12 In particular, we are interested in discerning the amount of funds spent on R & D by these new fi rms in the year prior to their going public, the cumulative amount spent on R & D prior to their going public, and which investors affect these amounts spent on R & D.
We incorporate work on tradable assets 13 and signaling theory 14, 15 in discussing our results to help explain differences in the relationships between investors and the amount spent on R & D for each of the two periods preceding the initial public offering (IPO). Specifi cally, we suggest that fi rms engaged in R & D that is supported by pre-IPO investors may send positive signals to post-IPO investors because of their higher levels of R & D spending. Our work should be of interest to researchers and practitioners trying to understand the amount spent on R & D of private fi rms seeking to go public and their sources of capital.
METHODOLOGY Data collection method
Our sample represents US biopharmaceutical fi rms that went public for the fi rst time between 1 January 1996 and 31 December 2007. Beginning in 1996, the Security & Exchange Commission ' s (SEC) internet site made publicly available the fi lings of all fi rms that were either publicly traded (for example, New York Stock Exchange; NASDAQ) or were fi ling to become publicly traded fi rms. We found most of the biopharmaceutical IPOs on the SEC ' s internet site; other sources accessed on the internet were Bio.org , Biospace, BioWorld, Edgar-Online, Ernst & Young, Hoover ' s and IPO Resources. We also read all news articles during this period related to public offerings from Biospace.com to ensure that all biopharmaceutical fi rms going public were captured. Plant and animal fi rms and foreign fi rms fi ling an F-1 foreign fi rm ' s registration statement were excluded. We included a small number of fi rms in our sample that appear to be foreign fi rms, but are incorporated in the United States and fi led an S-1 general registration statement for US fi rms. In addition, we excluded fi rms that did not receive any direct proceeds from the sale total assets), age, stage of clinical trial of the most developed or lead product, and number of US patents under the control of the fi rm. Our independent variables are venture capital investment, pharmaceutical ownership interest and strategic alliances that pay or promise to pay the biopharmaceutical fi rm a fee (that is, an initial, milestone or royalty fee). To determine venture capital investment, we cross-matched fi rms with individuals listed in the Principal Stockholders section of Pratt ' s Guide to Venture Capital Sources. 16 Multiple linear regressions were used to analyze these relationships for Drug fi rms. of their stock, but rather had the capital raised going solely to individual investors. As the SEC fi lings do not readily convey the date a fi rm goes public, we checked fi nance.yahoo. com and the appropriate stock exchanges ' (for example, NASDAQ) websites to fi nd and verify the date the fi rm ' s stock traded for the fi rst time.
RESULTS

Sample
Similar to Golec and Vernon, 6 we use US biopharmaceutical drug fi rms as they represent the fi rms creating new end-products for human consumption ( N = 158). These are fi rms with standard industrial classifi cation (SIC) codes 2834 (Pharmaceutical Preparations) and 2836 (Biological Products). 
Measures and statistical method
Our data come from the fi rm ' s prospectus as fi led with the SEC. The dependent variables are R & D expense by the fi rm in the year prior to its going public and the cumulative R & D expense of the fi rm prior to its IPO. We control for the fi rm ' s size (measured as per cent of the variance in R & D spending ( F = 17.761, P = 0.000). Our fi ndings do not show that investment by other biopharmaceutical fi rms or participation in strategic alliances was related to greater R & D investment. Interestingly, though not statistically signifi cant, the variable for other biopharmaceutical investors had a negative relationship with R & D spending. 17, 18 As Table 1 show drug fi rms divided by two 6-year time periods The last three columns in Table 1 We excluded eight outliers from our original sample of 158 Drug fi rms leaving us with 150 Drug fi rms. Table 1 
DISCUSSION
The present study takes a fi rst step toward understanding investments in R & D by private biopharmaceutical fi rms seeking to go public. We consider this an area of growing importance, as there are approximately 1100 private biopharmaceutical fi rms in the United States, many of which may go public in the near future or be acquired by other biopharmaceutical fi rms seeking to supplement their drug pipelines or add to their R & D capability. 12 As expected, we fi nd that fi rms receiving funding from venture capital fi rms tend to spend more on R & D at this time than fi rms without venture capital funding. There were no statistically signifi cant relationships found between R & D investment in the year preceding the IPO and biopharmaceutical fi rm investment or participation in strategic alliances. This is not exactly the case for cumulative amounts of R & D spending. Firms with venture capital and other biopharmaceutical fi rm investors spend greater amounts cumulatively on R & D than those that do not have these types of investors.
The implication for biopharmaceutical fi rms seeking to go public is that if they wish to spend more on R & D cumulatively, then they may need venture capital and / or other biopharmaceutical fi rm investors. However, if their primary goal is to spend greater amounts of funds on R & D just before going public, then it may be more advantageous to have venture capital investors than other biopharmaceutical fi rms, as either owners or strategic alliance partners. In other words, it appears that over time fi rms that wish to spend more on R & D need access to multiple sources of capital. Given the costs, venture capital alone may not be suffi cient to capitalize ongoing R & D in the long term in this industry.
Dierickx and Cool 13 suggest that fi rms deploy both tradable and non-tradable assets. Venture capitalist may view their investment solely in terms of tradable assets (for example, a fi rm). Biopharmaceutical fi rms may view their investment needs in terms of both tradable and non-tradable assets. Strategic alliances may represent a mechanism for biopharmaceutical fi rms to invest in specifi c tradable assets (for example, technologies). When considering buying non-tradable assets such as R & D capability, they have to invest in a tradable asset such as the fi rm itself. Thus, biopharmaceutical fi rm investors may employ two different strategies for two distinct purposes: acquisition of specifi c technology by way of strategic alliances, and acquisition of R & D capability by way of acquisition of the fi rm ' s common stock.
Given this, our fi ndings would suggest that biopharmaceutical fi rms follow the same type of process for both internal and external nontradable resources. In other words, fi rms may follow a prescribed, time-phased fl ow process in which they develop, accumulate and deploy tradable and non-tradable assets. Thus, biopharmaceutical fi rms investing in other biopharmaceutical fi rms invest in order to acquire the non-tradable asset of R & D capability, and they follow similar investment logic externally as they do internally. Hence, these fi rms may view competitive advantage also being built through R & D capability, which is a cumulative (not single year) process.
Signaling theory may also help to interpret our fi ndings. Proponents of this tradition suggest that signals convey market value to IPO investors. 19, 20 From this perspective, an entry. The IPO provides an exit vehicle for the venture capitalists, but for the biopharmaceutical fi rm investor, the IPO merely may represent another means in which to raise capital until a fi rm ' s product(s) is further developed; at that point, the biopharmaceutical fi rm investor may make the decision to purchase the fi rm or make a milestone payment. Hence, biopharmaceutical fi rm investors may be less concerned about ' signals ' (which may be what the negative direction of the biopharmaceutical fi rm ' s ownership interest variable is indicating in the one year prior to IPO model) and may represent a more focused approach to R & D spending on the part of other biopharmaceutical fi rms. This is congruent with our discussion above that noted that biopharmaceutical fi rms invest in different ways for tradable and non-tradable assets. Furthermore, given the fact that fewer fi rms are going public of late, another implication for practitioners is that private biopharmaceutical fi rms may need to rely to a greater extent on their pre-IPO investors for a longer period of time. This may require an increase in the number and type of pre-IPO investors (for example, venture capitalists, other biopharmaceutical fi rms) and inevitably may increase the cumulative amount of R & D spent before the IPO. This increase in funds over time may mean fi rms are less able to raise the volume of the signal in the year prior to the IPO. These implications are dependent upon the duration of the slowdown in the IPO market.
There also may be an alternative (and opposite) explanation that is related to our fi ndings and the IPO itself. Our fi ndings from the two regression models may mean that the other biopharmaceutical fi rms are less likely to invest further in the company, which creates the need to go public. Our results taken together show that biopharmaceutical fi rms over time are signifi cantly associated with R & D spending, but not in the year prior to the IPO. This may suggest that they have lost interest in the fi rm or are unwilling to invest interpretation of our fi ndings may be that the fi rms with venture capital investment are trying to raise the volume of the ' signals ' . The means of raising this volume of the signal may be through the staging of investments. 21 Pharmaceutical fi rms and venture capitalists ' stage ' their investments. Pharmaceutical fi rms engaged in strategic alliances stage their investments primarily based on milestone payments related to a product moving through the clinical trial process. For example, as a product moves from stage I to stage II of clinical trials the pharmaceutical fi rm may pay the nascent biopharmaceutical fi rm a prearranged payment to further the development of this product. Announcements of these changes in the product development efforts of biopharmaceutical fi rms can bring about changes in their stock market value. 22, 23 In addition to clinical advancements, venture capital fi rms also stage their investments based on other factors such as hiring management, establishing a board of directors and attracting additional investors. 24 A possible explanation of these results could suggest that venture capitalists may also stage their investments to coincide with an IPO, understanding that the potential payback period for such an investment is relatively short as venture capitalists typically divest themselves of their stock after the IPO and its ' lock-up ' period.
These signals may be of less importance to biopharmaceutical fi rms that invest in other biopharmaceutical fi rms because of their different purposes for investment. As noted above, biopharmaceutical fi rms invest in other fi rms in order to acquire the fi rm ' s technology or the fi rm itself in order to supplement resources and capabilities. Venture capitalists act as fi nancial intermediaries 25 until other private or public investors acquire their shares. Thus, the intention of investment by venture capitalists and biopharmaceutical fi rms might be different and may result in different levels of investment and at different times (for example, stages). This is to say that venture capitalists have an eye toward exit, whereas biopharmaceutical fi rms have an eye toward further. This may mean a negative signal to IPO investors; clearly, more research is needed in this area.
Limitations and conclusion
There are some limitations to our study. As we have studied only US biopharmaceutical fi rms, we do not know if our study ' s results are generalizable to other industries or fi rms in other countries. We study only fi rms going public as opposed to other private fi rms. The performance (that is, drugs developed or clinical libraries) related to these R & D expenditures is also unknown. Neither is the study very fi ne-grained, as we do not take into account the number of products pursued by the fi rms nor the amounts spent on each drug / therapy being pursued or the therapeutic class of the end-product. We did not examine the amounts invested by each type of investor. We also combine both pharmaceutical and biotechnology fi rms together, though the technology and knowledge related to both segments of this industry is different and at different stages of development. Thus, there are other factors worth understanding regarding these fi ndings, fi rms and industry.
In summary, the present study has examined factors associated with R & D spending of private biopharmaceutical fi rms prior to their going public. Similar to other work on large biopharmaceutical fi rms, our results show that emerging biopharmaceutical fi rms are spending increasing amounts of funds on R & D. Additionally, fi rms with venture capitalists and other biopharmaceutical fi rms are associated with higher cumulative R & D spending prior to their going public, but only venture capitalists are associated with higher R & D spending in the year prior to the IPO. The study ' s results add to our knowledge concerning nascent biopharmaceutical fi rms ' R & D expenditures and their relationship to their sources of capital. Based on these and other studies ' fi ndings related to biopharmaceutical spending, we can assume that the paradigm shift in new drug development and patient care attributable to biopharmaceutical products will continue into the future for some time to come.
